Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
May 27, 2026
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay
May 27, 2026
Lucid Diligence Brief: SELLAS REGAL AML Phase 3 Nears Final Analysis
May 27, 2026
Women’s Health Today—May 27, 2026
May 27, 2026
Immunology Today—May 27, 2026
May 27, 2026
Neuroscience Today—May 27, 2026
May 27, 2026
Lucid Diligence Brief: Unio Health Partners and Thesis Care partnership
May 27, 2026
Lucid Diligence Brief: Insilico and Human Longevity collaboration
May 26, 2026
Endocrinology Today—May 26, 2026
May 26, 2026
Obesity Today—May 26, 2026
May 26, 2026
AI in Healthcare and Digital Health Today—May 26, 2026
May 25, 2026